Basal activity of a PARP1-NuA4 complex varies dramatically across cancer cell lines

Cell Reports

Volumn 8, Issue 6, 2014, Pages 1808-1818

  Krukenberg, Kristin A ^a   Jiang, Ruomu ^a   Steen, Judith A ^a   Mitchison, Timothy J ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; HISTONE ACETYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PROTEIN NUA4; UNCLASSIFIED DRUG; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PROTEIN BINDING; PROTEIN SUBUNIT; SMALL INTERFERING RNA;

ANIMAL CELL; ARTICLE; BREAST CANCER CELL LINE; CELL LYSATE; CHROMATIN ASSEMBLY AND DISASSEMBLY; DNA DAMAGE; FRACTIONATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SUBUNIT; SUCROSE GRADIENT; ANTAGONISTS AND INHIBITORS; BREAST TUMOR; FEMALE; GENETICS; MCF 7 CELL LINE; METABOLISM; PATHOLOGY; RNA INTERFERENCE; TUMOR CELL LINE;

BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; HISTONE ACETYLTRANSFERASES; HUMANS; MCF-7 CELLS; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN BINDING; PROTEIN SUBUNITS; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84907418996     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2014.08.009     Document Type: Article

References (43)

1. Ahel I., Ahel D., Matsusaka T., Clark A.J., Pines J., Boulton S.J., West S.C. Poly(ADP-ribose)-binding zinc finger motifs in DNA repair/checkpoint proteins. Nature 2008, 451:81-85.
2. Audeh M.W., Carmichael J., Penson R.T., Friedlander M., Powell B., Bell-McGuinn K.M., Scott C., Weitzel J.N., Oaknin A., Loman N., et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010, 376:245-251.
3. Beneke S. Regulation of chromatin structure by poly(ADP-ribosyl)ation. Front Genet 2012, 3:169.
4. Chiou S.H., Jiang B.H., Yu Y.L., Chou S.J., Tsai P.H., Chang W.C., Chen L.K., Chen L.H., Chien Y., Chiou G.Y. Poly(ADP-ribose) polymerase 1 regulates nuclear reprogramming and promotes iPSC generation without c-Myc. J.Exp. Med. 2013, 210:85-98.
5. Cox J., Matic I., Hilger M., Nagaraj N., Selbach M., Olsen J.V., Mann M. A practical guide to the MaxQuant computational platform for SILAC-based quantitative proteomics. Nat. Protoc. 2009, 4:698-705.
6. Diefenbach J., Bürkle A. Introduction to poly(ADP-ribose) metabolism. Cell. Mol. Life Sci. 2005, 62:721-730.
7. Doege C.A., Inoue K., Yamashita T., Rhee D.B., Travis S., Fujita R., Guarnieri P., Bhagat G., Vanti W.B., Shih A., et al. Early-stage epigenetic modification during somatic cell reprogramming by Parp1 and Tet2. Nature 2012, 488:652-655.
8. Doyon Y., Côté J. The highly conserved and multifunctional NuA4 HAT complex. Curr. Opin. Genet. Dev. 2004, 14:147-154.
9. Doyon Y., Selleck W., Lane W.S., Tan S., Côté J. Structural and functional conservation of the NuA4 histone acetyltransferase complex from yeast to humans. Mol. Cell. Biol. 2004, 24:1884-1896.
10. Farmer H., McCabe N., Lord C.J., Tutt A.N.J., Johnson D.A., Richardson T.B., Santarosa M., Dillon K.J., Hickson I., Knights C., et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434:917-921.
11. Ferro A.M., Olivera B.M. Poly(ADP-ribosylation) invitro. Reaction parameters and enzyme mechanism. J.Biol. Chem. 1982, 257:7808-7813.
12. Garber K. PARP inhibitors bounce back. Nat. Rev. Drug Discov. 2013, 12:725-727.
13. Garnett M.J., Edelman E.J., Heidorn S.J., Greenman C.D., Dastur A., Lau K.W., Greninger P., Thompson I.R., Luo X., Soares J., et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 2012, 483:570-575.
14. Ginsburg D.S., Govind C.K., Hinnebusch A.G. NuA4 lysine acetyltransferase Esa1 is targeted to coding regions and stimulates transcription elongation with Gcn5. Mol. Cell. Biol. 2009, 29:6473-6487.
15. Hassa P.O., Hottiger M.O. The diverse biological roles of mammalian PARPS, a small but powerful family of poly-ADP-ribose polymerases. Front. Biosci. 2008, 13:3046-3082.
16. Huang S.M., Mishina Y.M., Liu S., Cheung A., Stegmeier F., Michaud G.A., Charlat O., Wiellette E., Zhang Y., Wiessner S., et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 2009, 461:614-620.
17. Huang W., Sherman B.T., Lempicki R.A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 2009, 4:44-57.
18. Javle M., Curtin N.J. The role of PARP in DNA repair and its therapeutic exploitation. Br. J. Cancer 2011, 105:1114-1122.
19. Ji Y., Tulin A.V. The roles of PARP1 in gene control and cell differentiation. Curr. Opin. Genet. Dev. 2010, 20:512-518.
20. Ji Y., Tulin A.V. Post-transcriptional regulation by poly(ADP-ribosyl)ation of the RNA-binding proteins. Int. J. Mol. Sci. 2013, 14:16168-16183.
21. Jones P., Altamura S., Boueres J., Ferrigno F., Fonsi M., Giomini C., Lamartina S., Monteagudo E., Ontoria J.M., Orsale M.V., et al. Discovery of 2-4-[(3S)-piperidin-3-yl]phenyl-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors. J.Med. Chem. 2009, 52:7170-7185.
22. Kleine H., Poreba E., Lesniewicz K., Hassa P.O., Hottiger M.O., Litchfield D.W., Shilton B.H., Lüscher B. Substrate-assisted catalysis by PARP10 limits its activity to mono-ADP-ribosylation. Mol. Cell 2008, 32:57-69.
23. Krishnakumar R., Kraus W.L. The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets. Mol. Cell 2010, 39:8-24.
24. Krishnakumar R., Kraus W.L. PARP-1 regulates chromatin structure and transcription through a KDM5B-dependent pathway. Mol. Cell 2010, 39:736-749.
25. Lord C.J., Ashworth A. Mechanisms of resistance to therapies targeting BRCA-mutant cancers. Nat. Med. 2013, 19:1381-1388.
26. Martello R., Mangerich A., Sass S., Dedon P.C., Bürkle A. Quantification of cellular poly(ADP-ribosyl)ation by stable isotope dilution mass spectrometry reveals tissue- and drug-dependent stress response dynamics. ACS Chem. Biol. 2013, 8:1567-1575.
27. Mendoza-Alvarez H., Alvarez-Gonzalez R. Poly(ADP-ribose) polymerase is a catalytic dimer and the automodification reaction is intermolecular. J.Biol. Chem. 1993, 268:22575-22580.
28. Neve R.M., Chin K., Fridlyand J., Yeh J., Baehner F.L., Fevr T., Clark L., Bayani N., Coppe J.-P., Tong F., et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006, 10:515-527.
29. Ogino H., Nozaki T., Gunji A., Maeda M., Suzuki H., Ohta T., Murakami Y., Nakagama H., Sugimura T., Masutani M. Loss of Parp-1 affects gene expression profile in a genome-wide manner in ES cells and liver cells. BMC Genomics 2007, 8:41.
30. Petesch S.J., Lis J.T. Activator-induced spread of poly(ADP-ribose) polymerase promotes nucleosome loss at Hsp70. Mol. Cell 2012, 45:64-74.
31. Pion E., Ullmann G.M., Amé J.-C., Gérard D., de Murcia G., Bombarda E. DNA-induced dimerization of poly(ADP-ribose) polymerase-1 triggers its activation. Biochemistry 2005, 44:14670-14681.
32. Schiewer M.J., Goodwin J.F., Han S., Brenner J.C., Augello M.A., Dean J.L., Liu F., Planck J.L., Ravindranathan P., Chinnaiyan A.M., et al. Dual roles of PARP-1 promote cancer growth and progression. Cancer Discov 2012, 2:1134-1149.
33. Schreiber V., Dantzer F., Ame J.C., de Murcia G. Poly(ADP-ribose): novel functions for an old molecule. Nat. Rev. Mol. Cell Biol. 2006, 7:517-528.
34. Simbulan-Rosenthal C.M., Rosenthal D.S., Luo R., Samara R., Espinoza L.A., Hassa P.O., Hottiger M.O., Smulson M.E. PARP-1 binds E2F-1 independently of its DNA binding and catalytic domains, and acts as a novel coactivator of E2F-1-mediated transcription during re-entry of quiescent cells into S phase. Oncogene 2003, 22:8460-8471.
35. Sousa F.G., Matuo R., Soares D.G., Escargueil A.E., Henriques J.A.P., Larsen A.K., Saffi J. PARPs and the DNA damage response. Carcinogenesis 2012, 33:1433-1440.
36. Tallis M., Morra R., Barkauskaite E., Ahel I. Poly(ADP-ribosyl)ation in regulation of chromatin structure and the DNA damage response. Chromosoma 2014, 123:79-90.
37. Tan E.S., Krukenberg K.A., Mitchison T.J. Large-scale preparation and characterization of poly(ADP-ribose) and defined length polymers. Anal. Biochem. 2012, 428:126-136.
38. Vyas S., Chesarone-Cataldo M., Todorova T., Huang Y.-H., Chang P. A systematic analysis of the PARP protein family identifies new functions critical for cell physiology. Nat Commun 2013, 4:2240.
39. Wahlberg E., Karlberg T., Kouznetsova E., Markova N., Macchiarulo A., Thorsell A.G., Pol E., Frostell Å., Ekblad T., Öncü D., et al. Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors. Nat. Biotechnol. 2012, 30:283-288.
40. Wang W., Dong L., Saville B., Safe S. Transcriptional activation of E2F1 gene expression by 17beta-estradiol in MCF-7 cells is regulated by NF-Y-Sp1/estrogen receptor interactions. Mol. Endocrinol. 1999, 13:1373-1387.
41. Wang M., Weiss M., Simonovic M., Haertinger G., Schrimpf S.P., Hengartner M.O., von Mering C. PaxDb, a database of protein abundance averages across all three domains of life. Mol. Cell. Proteomics 2012, 11:492-500.
42. Yamada H.Y. Human Tip60 (NuA4) complex and cancer. Colorectal Cancer Biology-From Genes to Tumor 2012, InTech, Rijeka, Croatia. R. Ettarh (Ed.).
43. Zahradka P., Ebisuzaki K. A shuttle mechanism for DNA-protein interactions. The regulation of poly(ADP-ribose) polymerase. Eur. J. Biochem. 1982, 127:579-585.